$85.92-0.43 (-0.50%)
Archer-Daniels-Midland Company provides human and animal nutrition ingredients and solutions in the United States, Switzerland, the Cayman Islands, Brazil, Mexico, Canada, the United Kingdom, and internationally.
Archer-Daniels-Midland Company in the Consumer Defensive sector is trading at $85.92 with a market capitalization of $38.5B. Wall Street consensus targets $75.30 (10 analysts), implying a -12.4% move over the next 12 months. The stock is currently near its 52-week high of $88.46, remaining 25.5% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $20.49B↑ | $18.56B↓ | $20.37B↓ | $21.17B↑ | $20.18B |
| Gross Profit | $1.22B↑ | $1.21B↓ | $1.27B↓ | $1.37B↑ | $1.18B |
| Operating Income | $261.00M↓ | $320.00M↓ | $397.00M↓ | $459.00M↑ | $248.00M |
| Net Income | $298.00M↓ | $456.00M↑ | $108.00M↓ | $219.00M↓ | $295.00M |
Archer-Daniels-Midland Company provides human and animal nutrition ingredients and solutions in the United States, Switzerland, the Cayman Islands, Brazil, Mexico, Canada, the United Kingdom, and internationally. It operates in three segments: Ag Ser...
Gevo, Inc. has appointed Todd Werpy, a veteran scientist and former Chief Science Officer at Archer-Daniels-Midland Company, to its Board as a Class II director, a role he began on August 20, 2026, with a term running through the 2027 annual stockholders’ meeting. Werpy’s background in commercializing bio-based technologies, carbon-efficient processes and biomass-derived chemicals adds deep technical and innovation-focused leadership that is directly aligned with Gevo’s low-carbon fuels and...
Archer-Daniels-Midland’s 28% return over the past six months has outpaced the S&P 500 by 20.1%, and its stock price has climbed to $86.22 per share. This run-up might have investors contemplating their next move.
CTVA's Q2 earnings may rise as premium seed demand, new products and productivity gains help offset pricing and inflation pressures.
SCI is poised for modest second-quarter revenue growth, supported by preneed cemetery sales and pricing, while soft funeral volumes may have pressured margins.
CHEF is likely to post Q2 sales and earnings growth as North American momentum and operating efficiencies offset cost and demand pressures.